Could This Biosimilar Drug Candidate Be a Winner for Amgen?

Could This Biosimilar Drug Candidate Be a Winner for Amgen?

Source: 
Motley Fool
snippet: 
  • The biotech giant shared encouraging results for its Soliris biosimilar.
  • The drug candidate could haul in $300 million in annual sales for Amgen.
  • The stock appears be a buy for dividend growth investors.